Anti-Human CD2 [Clone G11] — Purified in vivo PLATINUM™ Functional Grade

Anti-Human CD2 [Clone G11] — Purified in vivo PLATINUM™ Functional Grade

Product No.: C965

[product_table name="All Top" skus="C365"]

- -
- -
Clone
G11
Target
CD2
Formats AvailableView All
Product Type
Monoclonal Antibody
Isotype
Mouse IgG2a
Applications
Costim
,
FC
,
IHC
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Isotype Controls
Recommended Dilution Buffer
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this G11 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB
Additional Applications Reported In Literature ?
IHC
Costim
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone G11 recognizes an epitope of human CD2.
Background
CD2 is a 45-59 kD type I transmembrane glycoprotein belonging to the Ig superfamily. CD2 is the receptor for LFA-3/CD58. CD2 serves as an adhesion receptor that binds to CD58; generating the activation of CD2-positive T cells and NK cells and in the regulation of their cytolytic activities. CD2 is a specific marker for T cells and NK cells. Hence, it can be used in immunohistochemistry to identify the occurrence of these cells in tissue sections. The vast majority of T cell lymphomas and leukemias express CD2 which makes it possible to distinguish these conditions from B-cell lymphomas.
Antigen Distribution
CD2 is present on normal peripheral blood lymphocytes, thymocytes, mature circulating T-cells and a subset of NK cells.
Ligand/Receptor
CD58 (LFA-3), CD48, CD59, CD15
PubMed
NCBI Gene Bank ID
Research Area
Costimulatory Molecules
.
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Based on the available information, clone G11 has been developed and characterized for specific in vivo applications, though the search results primarily describe preclinical development rather than extensive in vivo mouse studies.

Tumor Targeting Applications

The G11 antibody, which is a human monoclonal antibody targeting domain C of tenascin-C, has been engineered specifically for tumor-targeting applications in vivo. Tenascin-C is overexpressed in various tumors, making it an attractive target for cancer therapy. The antibody demonstrates strong immunohistochemical staining of human tumor sections, indicating its potential utility for tumor targeting.

Antibody Format Engineering

To optimize in vivo performance, the G11 antibody has been cloned and expressed in multiple formats specifically designed for animal studies:

Small Immunoprotein (SIP) Format: The scFv(G11) was fused with a human εCH4 domain to create a 75 kDa bivalent miniantibody. This format has proven superior to conventional IgG and scFv formats for radioimmunotherapeutic applications, as it provides improved pharmacokinetics and tumor penetration.

Cytokine Fusion Proteins: The scFv(G11) was also fused with human interleukin-2 to create an immunocytokine fusion protein. Unlike similar constructs, the scFv(G11)-IL2 fusion proved to be exclusively monomeric under physiological conditions.

CD2-Targeting Applications

A separate G11 clone targeting human CD2 has been developed as a functional grade preclinical antibody for in vivo use. This antibody is manufactured under animal-free conditions with extremely low endotoxin levels (<0.5 EU/mg) and high purity (>95%), making it suitable for in vivo mouse studies. The antibody is tested and guaranteed to be free of mouse pathogens that could compromise experimental results.

Commonly used antibodies or proteins used in combination with G11 (an antibody targeting extra-domain C of tenascin-C) in the literature include:

  • scFv(L19): Frequently used as a comparator antibody. L19 is another antibody targeting a different epitope of tenascin-C. Both G11 and L19 have been engineered as single-chain variable fragments (scFv) and fused to other proteins for therapeutic purposes.
  • Interleukin-2 (IL-2): G11 has been genetically fused to IL-2 to generate a fusion protein (scFv(G11)-IL2) for targeted cytokine therapy.
  • SIP format (Small Immunoprotein): G11 scFv has been fused to the S2 isoform of human IgE, generating a bivalent antibody format for improved tumor targeting and retention.

Other antibody or protein strategies seen in the same field include:

  • Tumor-penetrating peptides like iRGD: These have been conjugated to tenascin-C antibodies (not always specifically G11, but targeting the same antigen) for improved tumor delivery and penetration of cancer drugs.
  • Monoclonal antibodies against tumor-associated antigens: In the context of tenascin-C research, antibodies like Herceptin (trastuzumab, anti-HER2) are often used as reference or comparator therapeutic antibodies to benchmark the performance of G11-based therapies.

In summary, the most commonly used antibodies or proteins with G11 in research are:

  • L19 antibody (as control or comparator)
  • Cytokine fusions, notably IL-2
  • Bivalent antibody formats (e.g., SIP-G11)
  • Tumor-penetrating peptides such as iRGD (in related strategies targeting tenascin-C)

These combinations optimize tumor targeting, immune cell recruitment, and drug delivery for cancer therapeutics based on G11.

The term "clone G11" appears in multiple contexts within scientific literature, most notably as an antibody clone targeting tenascin-C extra-domain C for tumor targeting, but also as unrelated clones (e.g., G11-6 for feline PD-L1, G11.2 for hybridoma sequencing, and others). The most significant and well-cited body of findings concerns the G11 antibody against tenascin-C, particularly in cancer research.

Key findings for the G11 (tenascin-C) antibody clone:

  • High-Affinity Tumor Targeting: G11 is a human antibody with high affinity (dissociation constant (K_D = 4.2) nM) for the extra-domain C of tenascin-C, an extracellular matrix protein overexpressed in various solid tumors, including high-grade astrocytomas and most lung cancers.
  • Tumor Selectivity: Immunohistochemistry demonstrated that G11 strongly stains several classes of lung cancers but shows no detectable staining in normal tissues, confirming its specificity for tumor-associated tenascin-C isoforms.
  • Versatile Formats for Therapy and Imaging: The G11 antibody has been successfully engineered into different formats—such as scFv (single-chain variable fragment), SIP (small immunoprotein) bivalent mini-antibody, and a fusion protein with interleukin-2—for improved tumor targeting and potential therapeutic or imaging applications.
  • Functional Enhancement: Fusion of G11 to the tumor-penetrating peptide iRGD further enhances its ability to target integrins (αVβ3) in a cell-free system, suggesting utility for improved drug delivery into tumors.
  • Preclinical Promise: In rodent models, G11 demonstrates effective and selective targeting of solid tumors, supporting its further development for clinical imaging and targeted cancer therapy.

Additional uses of similarly named clones ("G11") in literature:

  • G11-6 (anti-feline PD-L1): Used to detect endogenous PD-L1 in feline tumor cell lines, relevant for immuno-oncology research in veterinary medicine.
  • G11.2 hybridoma: Studied in hybridoma sequence homogeneity research, unrelated to cancer targeting.
  • Anti-mouse CXCL10 G11: A clone developed for pH-dependent antibody binding studies, not related to tenascin-C or tumor imaging.

Summary Table: Contexts of Notable ‘G11’ Clones in Literature

CloneTarget/UseOrganism/FieldKey Finding/RoleReference
G11 (tenascin-C)Tenascin-C extra-domain CHuman/cancer therapySpecific high-affinity targeting of solid tumors
G11-6Feline PD-L1Feline/immuno-oncologyMonoclonal antibody for flow cytometry
G11.2N/A (hybridoma sequencing)Mouse/ImmunologyHomogeneity in VH sequence analysis
G11 (anti-CXCL10)Mouse CXCL10Mouse/antibody designpH-dependent binding and neutralization properties

When citing "clone G11" in the context of cancer research and molecular imaging, findings overwhelmingly point to its value as a selective, high-affinity antibody for tumor targeting via tenascin-C. Other cited "G11" clones are clearly distinct and must not be conflated with the tumor-targeting antibody.

The dosing regimens for clone G11, specifically in the context of tenascin-C antibodies, are not explicitly detailed in the provided search results. However, one relevant study mentions the use of iRGD fusion to ScFv G11 antibodies in U87-MG mice, which improved tumor targeting but does not specify dosing regimens for clone G11 itself.

For other antibodies, dosing regimens typically depend on the specific target, application, and mouse model. For example, antibodies like anti-CTLA-4 (e.g., 9H10 and 9D9) are commonly used in cancer immunotherapy with doses ranging from 100 to 250 μg per mouse, administered intraperitoneally every 3 days. Similarly, anti-IL-4 (clone 11B11) is dosed at 1 mg per mouse every 4-5 days in tumor models.

To determine the specific dosing regimen for clone G11 across different mouse models, it would be necessary to consult specific studies or literature related to the use of this clone in various experimental settings.

References & Citations

1. Stern, LJ. et al. (2005) Proc Natl Acad Sci U S A.102(10):3744-9 PubMed
2. Woetmann, Anders et al. (2010) Experimental Dermatology 19: 1096–1102. Article Link
3. Meuer, S.C. et al. (1984) Cell 36:897
4. Peterson, A. and Sneed, B. (1987) Nature 329:842
5. Bierer, B.E. et al. (1989) Annu. Rev Immunol. 7:579
6. Krensky, C.F. et al. (1982) Proc. Natl. Acad. Sci. USA 79:7489
7. Krensky, C.F. et al. (1983) J. Immunol. 131:611
Costim
Flow Cytometry
IHC
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.